FDA approves dapagliflozin for heart failure with reduced ejection fraction
In a trial, dapagliflozin was found to reduce CV deaths and hospitalisations for heart failure as compared to placebo at 18 months. Approval is for use in adults with NYHA class II-IV heart failure with reduced ejection fraction. EU regulatory review is also underway.
Source:
US Food and Drug Administration